Compositions and methods for treating arthritis

Abstract

This disclosure relates to a composition for treating arthritis, comprising astaxanthin, a seaweed calcium composition, collagen, hyaluronic acid, calcium fructose borate, Terminalia chebula extract, and palm fruit extract. This disclosure also relates to a method of treating arthritis, comprising applying the disclosed composition to an individual to achieve a relieving effect on arthritis symptoms.

Description

Technical Field

[0001] This disclosure relates to compositions and methods for relieving and treating symptoms of arthritis, and more particularly to compositions and methods for relieving and treating osteoarthritis. Prior Technology

[0002] Arthritis refers to inflammation of the joints, leading to swelling, stiffness, pain, or reduced range of motion. Common causes of arthritis include age, overuse, and disease (e.g., infections or autoimmune diseases affecting the joint area). The most common types of arthritis are degenerative arthritis (or osteoarthritis) and rheumatoid arthritis, with degenerative arthritis being particularly associated with age and overuse. As developed and advanced countries age, and with increasing obesity and a growing awareness of physical activity leading to overuse of joints, the demand for relief and treatment of degenerative arthritis is growing. Summary of the Invention

[0003] This disclosure relates to a composition for treating arthritis, wherein per 1000 mg dose, the composition comprises: 1 to 10 mg of astaxanthin; 30 to 200 mg of a seaweed calcium composition containing at least 10% by weight of calcium; 5 to 100 mg of collagen; 20 to 150 mg of hyaluronic acid; 5 to 50 mg of calcium fructose borate; 100 to 500 mg of Terminalia chebula extract; and 100 to 500 mg of palm fruit extract.

[0004] This disclosure also relates to a method for treating arthritis, which includes administering the disclosed composition to an individual. Simple Explanation of the Diagram

[0005] Figure 1 shows the rate of change in body weight of rats in the control and experimental groups during the experiment. This rate of change in body weight was calculated using the following formula: {(Weekly body weight - Pre-experiment body weight) / Pre-experiment body weight} × 100%. Values ​​are expressed as mean ± SEM; * p < 0.05, ** p < 0.01.

[0006] Figure 2 shows the water intake records of rats in the control and experimental groups during the experiment. This water intake is the total weekly water intake, calculated using the following formula: total weekly water intake / number of rats per cage. Values ​​are expressed as mean ± SEM; *p < 0.05, **p < 0.01.

[0007] Figure 3 shows the food intake records of rats in the control and experimental groups during the experiment. This food intake is the total weekly food intake, calculated using the following formula: total weekly food intake / number of rats per cage. Values ​​are expressed as mean ± SEM; *p < 0.05, **p < 0.01.

[0008] Figure 4 shows the ratio of right and left knee widths in rats in the control and experimental groups during the experiment. Values ​​are expressed as mean ± SEM; * p < 0.05, ** p < 0.01.

[0009] Figure 5A shows a stained tissue section, revealing the right knee joint of the control group rats at the time of surgery. The black arrows indicate the lesions in the articular cartilage.

[0010] Figure 5B is a stained tissue section photograph showing the right knee joint of the experimental group rats at the time of surgery. The black arrows indicate the cartilage lesions on the articular surface.

[0011] Figure 5C shows stained tissue sections, illustrating the recovery of the right knee joint in the control group rats one month after surgery. The black arrows indicate lesions in the articular cartilage.

[0012] Figure 5D is a stained tissue section photograph, showing the recovery of the right knee joint of the rats in the experimental group one month after surgery. The black arrows indicate the lesions in the articular cartilage.

[0013] Figure 5E shows stained tissue sections, illustrating the recovery of the right knee joint in the control group rats two months post-surgery. The black arrows indicate lesions in the articular cartilage.

[0014] Figure 5F shows stained tissue sections, illustrating the recovery of the right knee joint in the experimental group rats two months post-surgery. The black arrows indicate lesions in the articular cartilage.

[0015] Figure 5G is a stained tissue section photograph showing a joint of a normal rat (without surgically induced joint damage). Implementation

[0016] The treatment of arthritis in the field is still focused on pain relief, in conjunction with adjuvant therapies to manage symptoms and avoid the frequency of joint inflammation. Clinically, there are a variety of painkillers available for medical practitioners to choose from to relieve pain, such as non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, Ibuprofen, Indomethacin, and Naproxen. However, painkillers are mostly used when pain occurs, and given the risk of drug side effects, these drugs are not suitable for long-term use and are not recommended for use to prevent the occurrence of arthritis. Adjuvant therapies focus on changing lifestyle or exercise habits to reduce the burden on the joints. Common practices include controlling and maintaining an appropriate weight, avoiding excessive exercise and ensuring adequate rest, wearing joint braces during exercise or daily activities, and applying heat or massage to relieve muscle tightness and promote blood circulation. The effectiveness of these adjuvant therapies is limited and often depends on patient compliance.

[0017] In addition, due to the gradual prevalence of arthritis and the attention of academia and industry, there are also many health nutrition products advocating joint care. These health nutrition products mostly claim to use emerging and scarce natural ingredients. However, even though these natural ingredients have been proven to be effective in relieving arthritis symptoms in academic studies, their efficacy is questionable due to their high price. Accordingly, novel compositions are needed in the field, which combine a variety of arthritic soothing active ingredients in appropriate proportions to produce an integrated effect, thereby achieving the same or better results with reduced dosage of individual ingredients.

[0018] The Disclosure Composition

[0019] This disclosure provides a composition for treating arthritis. As used herein, "treating" arthritis means relieving or improving arthritis symptoms in an individual, wherein the symptoms may be those diagnosed by a medical professional or self-diagnosed by the individual. For example, the relief or improvement of arthritis symptoms includes, but is not limited to, reducing joint pain, relieving joint inflammation, increasing joint range of motion, or a combination thereof; wherein the terms "relief," "soothing," or "improvement" are relative to a condition before the application of the disclosed composition, and the degree may be diagnosed by a medical professional or self-diagnosed by the individual. "Treatment" as used herein may also include providing a preventative effect for individuals at risk of having or developing the disease or symptoms (e.g., recurrence).

[0020] In many embodiments, the disclosed composition comprises astaxanthin, a seaweed calcium composition, collagen, hyaluronic acid, calcium fructose borate, Terminalia chebula extract, and palm fruit extract. In a dose of 1000 mg, the composition comprises 1 to 10 mg of astaxanthin, 30 to 200 mg of the seaweed calcium composition, 5 to 100 mg of collagen, 20 to 150 mg of hyaluronic acid, 5 to 50 mg of calcium fructose borate, 100 to 500 mg of Terminalia chebula extract, and 100 to 500 mg of palm fruit extract. In one specific embodiment, the disclosed composition comprises about 4 mg of astaxanthin, 95 mg of a seaweed calcium composition (containing 10 to 50 percent by weight of calcium), 40 mg of non-denatured type II collagen, 80 mg of hyaluronic acid, 25 mg of calcium fructose borate, 250 mg of Terminalia chebula extract, and 350 mg of palm fruit extract.

[0021] In some specific embodiments, the disclosed composition is substantially composed of 1 to 10 mg of astaxanthin, 30 to 200 mg of a seaweed calcium composition, 5 to 100 mg of collagen, 20 to 150 mg of hyaluronic acid, 5 to 50 mg of fructose borate calcium, 100 to 500 mg of Terminalia chebula extract, and 100 to 500 mg of palm fruit extract; or substantially composed of about 4 mg of astaxanthin, 95 mg of a seaweed calcium composition (containing 10 to 50% by weight calcium), 40 mg of non-denatured type II collagen, 80 mg of hyaluronic acid, 25 mg of fructose borate calcium, 250 mg of Terminalia chebula extract, and 350 mg of palm fruit extract. The phrase "substantially composed of..." means that the composition does not contain other ingredients with analgesic, anti-inflammatory, joint-strengthening, or combinations thereof, but does not exclude the inclusion of ingredients with other effects.

[0022] Astaxanthin. Astaxanthin is a natural, fat-soluble red pigment, a keto-carotenoid, IUPAC named 3,3'-Dihydroxy-β,β-carotene-4,4'-dione. The structure of astaxanthin contains hydroxyl and ketone groups extending to long carbon chains. These long carbon chains and hydroxyl groups provide astaxanthin with its amphibolic properties, and the length of the long carbon chain is sufficient for astaxanthin to cross the cell membrane, thus providing antioxidant effects both inside and outside the cell. Astaxanthin was first discovered and purified from lobster shells. Subsequently, the scientific community confirmed its presence in other organisms, such as Haematococcus pluvialis, Adonis aestivalis, Antarctic krill (Euphratica supurba), salmon, and red snapper, with Haematococcus pluvialis showing the highest content. In some embodiments, the astaxanthin in the disclosed composition is not limited; in many specific embodiments, the astaxanthin is purified from Haematococcus pluvialis or Antarctic krill.

[0023] In many embodiments, the compositions disclosed herein contain about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg of astaxanthin per 1000 mg dose, or any range defined by the two endpoints of the foregoing, such as: 1 to 10 mg, 1 to 9 mg, 1 to 8 mg, 1 to 7 mg, 1 to 6 mg, 1 to 5 mg, 1 to 4 mg, 1 to 3 mg, 1 to 2 mg, 2 to 10 mg, 2 to 9 mg, 2 to 8 mg, 2 to 7 mg, 2 to 6 mg, 2 to 5 mg, 2 to 4 mg, 2 to 3 mg, 3 to 10 mg, 3 to 9 mg, 3 to 8 mg, 3 to 7 mg. Astaxanthin in doses of 3 to 6 mg, 3 to 5 mg, 3 to 4 mg, 4 to 10 mg, 4 to 9 mg, 4 to 8 mg, 4 to 7 mg, 4 to 6 mg, 4 to 5 mg, 5 to 10 mg, 5 to 9 mg, 5 to 8 mg, 5 to 7 mg, 5 to 6 mg, 6 to 10 mg, 6 to 9 mg, 6 to 8 mg, 6 to 7 mg, 7 to 10 mg, 7 to 9 mg, 7 to 8 mg, 8 to 10 mg, 8 to 9 mg, or 9 to 10 mg. In a particular embodiment, the disclosed composition contains about 4 mg of astaxanthin per 1000 mg dose.

[0024] Depending on the optical activity of the hydroxyl groups at both ends of the astaxanthin structure, astaxanthin possesses levorotatory (3S-3S'), meso (3R-3S'), and dextrorotatory (3R-3R') structures. In many embodiments, the astaxanthin in the compositions disclosed herein comprises levorotatory astaxanthin, meso astaxanthin, and / or dextrorotatory astaxanthin. In many embodiments, the astaxanthin in the compositions disclosed herein comprises approximately 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, and 95%. Or 100% molar percentage of L-astaxanthin, or any range defined by the two endpoints above, such as: 20% to 100%, 20% to 95%, 20% to 90%, 20% to 85%, 20% to 80%, 20% to 75%, 20% to 70%, 20% to 65%, 20% to 60%, 20% to 55%, 20% to 50%, 20% to 45%, 20% to 40%, 20% to 35%, 20% to 30 ... 25% to 30%, 30% to 100%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, 30% to 55%, 30% to 50%, 30% to 45%, 30% to 40%, 30% to 35%, 40% to 100%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80% 40% to 75%, 40% to 70%, 40% to 65%, 40% to 60%, 40% to 55%, 40% to 50%, 40% to 45%, 50% to 100%, 50% to 95%, 50% to 90%, 50% to 85%, 50% to 80%, 50% to 75%, 50% to 70%, 50% to 65%, 50% to 60%, 50% to 55%, 60% to 100%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 70% to 100%, 70% to 95%, 70% to 90%, 70% to 85%, 70% to 80%, 70% to 75%, 80% to 100%, 80% to 95%, 80% to 90%, 80% to 85%, 90% to 100%, 90% to 95%, or 95% to 100% L-astaxanthin.

[0025] Seaweed calcium composition. The seaweed calcium composition disclosed herein refers to a composition containing calcified seaweed, comprising at least 10, 12, 15, 18, 20, 25, 30, 32, 35, 40, 45, or 50 wt% calcium, or any range defined by the two endpoints of the foregoing, such as: 10 to 50 wt%, 10 to 45 wt%, 10 to 40 wt%, 10 to 35 wt%, 10 to 32 wt%, 10 to 30 wt%, 10 to 25 wt%, 10 to 20 wt%, 10 to 18 wt%, 10 to 15 wt%, 10 to 12 wt%, 15 to 50 wt%, 15 to 45 wt%, 15 to 40 wt%, 15 to 35 wt%, 15 to 32 wt%, 15 to 30 wt%, 15 to 25 wt%. 15 to 20 wt%, 15 to 18 wt%, 20 to 50 wt%, 20 to 45 wt%, 20 to 40 wt%, 20 to 35 wt%, 20 to 32 wt%, 20 to 30 wt%, 20 to 25 wt%, 25 to 50 wt%, 25 to 45 wt%, 25 to 40 wt%, 25 to 35 wt%, 25 to 32 wt%, 25 to 30 wt%, 30 to 50 wt%, 30 to 45 wt%, 30 to 40 wt%, 30 to 35 wt%, 30 to 32 wt%, 32 to 50 wt%, 32 to 45 wt%, 32 to 40 wt%, or 32 to 35 wt% calcium. In some specific embodiments, the algae refers to red algae (Lithothamnions p.).

[0026] In many embodiments, the seaweed calcium composition further comprises at least one micronutrient selected from the group consisting of: magnesium, phosphorus, sulfur, iron, boron, fluoride, sodium, cobalt, copper, zinc, selenium, molybdenum, iodine, manganese, and nickel. In many specific embodiments, the seaweed calcium composition further comprises about 2, 2.2, 2.5, 3, 3.5, or 4 wt% magnesium, or any range defined by the two endpoints above, such as: 2 to 4 wt%, 2 to 3.5 wt%, 2 to 3 wt%, 2 to 2.5 wt%, 2.2 to 4 wt%, 2.2 to 3.5 wt%, 2.2 to 3 wt%, or 2.2 to 2.5 wt% magnesium.

[0027] In many embodiments, the calcium in the algal calcium composition (i.e., the calcified algae) has a honeycomb-like porous structure. Without being limited by any theory, this disclosure suggests that this honeycomb-like porous structure contributes to superior bioavailability, making the algal calcium more bioavailable than calcium carbonate. In many embodiments, the calcium in the algal calcium composition has a polymorph comprising 60% to 70% calcite, 20% to 30% aragonite, and 10% to 20% vaterite. In some specific embodiments, the polymorph comprises approximately 65% ​​calcite, approximately 23% aragonite, and approximately 12% vaterite.

[0028] In many embodiments, the compositions disclosed herein contain about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg of seaweed calcium composition (wherein the seaweed calcium composition contains at least 10% by weight calcium), or any range defined by the two endpoints of the foregoing, such as: 50 to 100 mg, 50 to 95 mg, 50 to 90 mg, 50 to 85 mg, 50 to 80 mg, 50 to 75 mg, 50 to 70 mg, 50 to 60 mg, 50 to 55 mg, 60 to 100 mg, 60 to 95 mg, 60 to 90 mg, 60 to 85 mg, 60 to 80 mg A composition of seaweed calcium in grams, 60 to 75 mg, 60 to 70 mg, 70 to 100 mg, 70 to 95 mg, 70 to 90 mg, 70 to 85 mg, 70 to 80 mg, 70 to 75 mg, 80 to 100 mg, 80 to 95 mg, 80 to 90 mg, 80 to 85 mg, 90 to 100 mg, 90 to 95 mg, or 50 to 100 mg, wherein the seaweed calcium composition contains at least 10% by weight calcium or the calcium content described in this specification. In a particular embodiment, each 1000 mg dose of the disclosed composition contains about 95 mg of the seaweed calcium composition.

[0029] Collagen. In many embodiments, the collagen contained in the compositions disclosed herein is type II collagen. In many specific embodiments, the collagen contained in the compositions disclosed herein is undenatured type II collagen, which has a triple helix structure. In many specific embodiments, this collagen is not hydrolyzed collagen. Without any theoretical limitations, this disclosure suggests that hydrolyzed collagen has a small molecular weight and is easily absorbed by the human body and broken down into materials required for collagen synthesis in the human body. The mechanism of action of undenatured type II collagen is to regulate humoral immune response and cellular immune response through oral tolerance via interaction with gut-associated lymphoid tissue. It is known that undenatured type II collagen is absorbed by Treg cells in Peyer's patch in the human small intestine and activates these Treg cells. Activated Treg cells circulate throughout the body and, upon recognizing type II collagen at the site of joint inflammation, release regulatory factors to soothe the inflammatory response.

[0030] In many embodiments, the compositions disclosed herein contain about 20, 25, 30, 35, 40, 45, 50, 55, or 60 mg of collagen per 1000 mg dose, or any range defined by the two endpoints of the foregoing, such as: 20 to 60 mg, 20 to 55 mg, 20 to 50 mg, 20 to 45 mg, 20 to 40 mg, 20 to 35 mg, 20 to 30 mg, 20 to 25 mg, 30 to 60 mg, 30 to 55 mg, 30 to 50 mg, 30 to 45 mg, 30 to 40 mg, 30 to 35 mg, 35 to 60 mg, 35 to 55 mg, 35 to 50 mg, 35 to 45 mg, or 35 to 40 mg of collagen per 1000 mg dose. In one particular embodiment, the compositions disclosed herein contain about 40 mg of the seaweed calcium composition per 1000 mg dose.

[0031] Hyaluronic acid. Hyaluronic acid, also known as hyaluronan, is a disaccharide polymer composed of D-glucosamine and N-acetylglucosamine. Without any theoretical limitations, this disclosure proposes that hyaluronic acid, upon binding to the Toll-Like Receptor 4 (TLR-4) receptor on epithelial cells in the intestine, can promote the secretion of the anti-inflammatory factor IL-10, thereby increasing the activity of the suppressor of cytokine signaling 3 (SOCS3), thus achieving an anti-inflammatory effect. Furthermore, without any theoretical limitations, this disclosure suggests that the efficacy of hyaluronic acid is closely related to its molecular weight. In many embodiments, the hyaluronic acid contained in the compositions disclosed herein has a weight-average molecular weight (Mw) of 5, 10, 20, 50, 100, 200, 500, 600, 700, 800, 900, or 1000 kDa, or any range defined by the two endpoints of the foregoing, such as: 5 to 1000 kDa, 5 to 900 kDa, 5 to 800 kDa, 5 to 700 kDa, 5 to 600 kDa, 5 to 500 kDa, 5 to 200 kDa, 5 to 100 kDa, 5 to 50 kDa, 5 to 20 kDa, 20 to 1000 kDa, 20 to 900 kDa, 20 to 800 kDa, 20 to 700 kDa, 20 to 600 kDa, 20 to 500 kDa, 20 to 2 ... kDa, 20 to 100, 20 to 50 kDa, 200 to 1000 kDa, 200 to 900 kDa, 200 to 800 kDa, 200 to 700 kDa, 200 to 600 kDa, 200 to 500 kDa, 500 to 1000 kDa, 500 to 900 kDa, 500 to 800 kDa, 500 to 700 kDa, or 500 to 600 kDa.

[0032] In many embodiments, the compositions disclosed herein contain about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg of hyaluronic acid per 1000 mg dose, or any range defined by the two endpoints of the foregoing, such as: 50 to 100 mg, 50 to 90 mg, 50 to 80 mg, 50 to 70 mg, 50 to 60 mg, 60 to 100 mg, 60 to 90 mg, 60 to 80 mg, 60 to 75 mg, 60 to 70 mg, 70 to 100 mg, 70 to 90 mg, 70 to 80 mg, 80 to 100 mg, 80 to 90 mg, or 90 to 100 mg of hyaluronic acid per 1000 mg dose. In many specific embodiments, the compositions disclosed herein contain about 80 mg of hyaluronic acid per 1000 mg dose. In some embodiments, the hyaluronic acid may be derived from animals (such as rooster combs) or from microorganisms.

[0033] Calcium fructoborate. Calcium fructoborate is a mineral borate complex with the chemical formula Ca[(C6H10O6)2B]2. In many embodiments, the compositions disclosed herein contain about 10, 15, 20, 25, or 30 mg of calcium fructoborate per 1000 mg dose, or any range defined by the two endpoints above, such as: 10 to 30 mg, 10 to 25 mg, 10 to 20 mg, 10 to 15 mg, 15 to 30 mg, 15 to 25 mg, 15 to 20 mg, or 20 to 30 mg of calcium fructoborate. In many specific embodiments, the compositions disclosed herein contain about 25 mg of calcium fructoborate per 1000 mg dose.

[0034] Terminalia chebula extract. In many embodiments, the Terminalia chebula extract in the disclosed compositions is a water-soluble extract, for example, a Terminalia chebula pericarp extract. In many embodiments, the Terminalia chebula extract comprises chebulinic acid, chebulagic acid, or a combination thereof. In many embodiments, the Terminalia chebula extract further comprises a hydrolysable tannoid.

[0035] In many specific embodiments, the Terminalia chebula extract contains about 10, 12, 15, 18, 20, 25, or 30 wt% of chebulic acid, or any range defined by the two endpoints above, such as: 10 to 30 wt%, 10 to 25 wt%, 10 to 20 wt%, 10 to 15 wt%, 15 to 30 wt%, 15 to 25 wt%, 15 to 20 wt%, 15 to 18 wt%, 20 to 30 wt%, or 20 to 25 wt% of chebulic acid. In many specific embodiments, the Terminalia chebula extract contains about 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, or 25 wt% of chebulic tannic acid, or any range defined by the two endpoints above, such as: 5 to 25 wt%, 5 to 20 wt%, 5 to 15 wt%, 5 to 10 wt%, 8 to 25 wt%, 8 to 20 wt%, 8 to 15 wt%, 8 to 10 wt%, 15 to 25 wt%, or 15 to 20 wt% of chebulic tannic acid. In many specific embodiments, the Terminalia chebula extract contains about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt% of hydrolyzable tannins, or any range defined by the two endpoints above, such as: 5 to 50 wt%, 5 to 45 wt%, 5 to 40 wt%, 5 to 35 wt%, 5 to 30 wt%, 5 to 25 wt%, 5 to 20 wt%, 5 to 15 wt%, 5 to 10 wt%, 15 to 50 wt%, 15 to 45 wt%, 15 to 40 wt%, 15 to 35 wt%, 15 to 30 wt%, 15 to 25 wt%, 15 to 20 wt%, 25 to 50 wt%, 25 to 45 wt%, 25 to 40 wt%, 25 to 35 wt%, 25 to 30 wt%, 35 to 50 wt%. The extract contains 35 to 45 wt% or 35 to 40 wt% hydrolyzable tannins. In one specific embodiment, the Terminalia chebula extract contains 15 to 30 wt% chebulic acid, 8 to 25 wt% chebulic tannic acid, and 5 to 45 wt% hydrolyzable tannins.

[0036] In many embodiments, the Terminalia chebula extract is obtained by: obtaining Terminalia chebula pericarp, grinding the pericarp to obtain a powder, extracting the powder with water to obtain a water-soluble extract of Terminalia chebula pericarp, and drying the water extract of Terminalia chebula pericarp to obtain an extract powder. In many embodiments, the drying is achieved by spray drying or freeze drying. In many embodiments, the extraction step is carried out at 25°C for 10 to 20 hours (e.g., 12 to 16 hours, or 12, 13, 14, 15, or 16 hours), or at 40°C for 1 to 10 hours (e.g., 1 to 6 hours, or 1, 2, 3, 4, 5, or 6 hours).

[0037] In many embodiments, the compositions disclosed herein contain about 200, 220, 240, 250, 260, 280, or 300 mg of the Terminalia chebula extract per 1000 mg dose, or any range defined by the two endpoints above, such as: 200 to 300 mg, 200 to 280 mg, 200 to 260 mg, 200 to 250 mg, 200 to 240 mg, 200 to 220 mg, 220 to 300 mg, 220 to 280 mg, 220 to 260 mg, 220 to 250 mg, or 220 to 240 mg of the Terminalia chebula extract. In many specific embodiments, the compositions disclosed herein contain about 250 mg of the Terminalia chebula extract per 1000 mg dose.

[0038] Palm fruit extract. In many embodiments, the palm fruit extract of the compositions disclosed herein contains palmoylethanolamide (PEA). Unlike other inflammatory mediators, the content of PEA in human tissues decreases during inflammation. Without being limited by any theory, this disclosure suggests that increasing PEA levels may help increase the concentration of anandamide (AEA) in the body, thereby relieving pain. Furthermore, PEA can activate CB2 receptors, thereby controlling inflammation through the COX-2 pathway.

[0039] In many embodiments, the palm fruit extract is obtained by the following method: obtaining palm fruit, threshing the palm fruit to obtain threshed palm fruit, steaming the threshed palm fruit, drying and grinding the steamed palm fruit to obtain palm fruit powder, and then extracting the palm fruit powder with ethanol to obtain a crude palm fruit extract. In some embodiments, the method further includes concentrating the crude palm fruit extract to obtain a first extract. In some embodiments, the method further includes extracting the first extract again with ethanol and drying the product to obtain a second extract. In some embodiments, the method further includes extracting the second extract again with ethanol and drying the product to obtain a third extract. In many embodiments, the method further includes drying the obtained first, second, or third extract to obtain a powdered palm fruit extract. In many embodiments, the drying is performed by vacuum drying or freeze drying. In many embodiments, the method further comprises mixing the powdered palm fruit extract with an excipient, wherein the excipient may be, but is not limited to, lecithin, coconut oil, or silicon dioxide.

[0040] In many embodiments, the compositions disclosed herein contain about 200, 225, 250, 275, 300, 325, 350, 375, or 400 mg of the palm fruit extract per 1000 mg dose, or any range defined by the two endpoints above, such as: 200 to 400 mg, 200 to 375 mg, 200 to 350 mg, 200 to 300 mg, 200 to 250 mg, 250 to 400 mg, 250 to 375 mg, 250 to 350 mg, 250 to 300 mg, 300 to 400 mg, 300 to 375 mg, or 300 to 350 mg of the palm fruit extract. In many specific embodiments, the compositions disclosed herein contain about 350 mg of the Terminalia chebula extract per 1000 mg dose.

[0041] This disclosure discloses a method for preparing the composition. The disclosed composition can be prepared by more than one method, as long as the resulting composition contains the components indicated in this disclosure and in the amounts shown in this disclosure. In some specific embodiments, the method for preparing the disclosed composition involves weighing the components sequentially according to the desired amounts, for example, weighing 100-200 grams of Haematococcus pluvialis powder (containing 2.5% astaxanthin), 50-120 grams of red algae calcium, 20-60 grams of non-denatured type II collagen, 80 grams of cockscomb extract (containing 60-75% hyaluronic acid), 10-40 grams of fructose borate calcium, 100-300 grams of Terminalia chebula extract, and 200-500 grams of palm fruit extract, and thoroughly mixing these components to form a total of 1000 grams of raw material composition. This raw material composition can then be formulated into the desired dosage form for consumer use.

[0042] In many embodiments, the composition may be formulated as an oral composition. In many embodiments, when the composition is an oral composition, the oral composition may be, but is not limited to, a powder, granules, tablets, capsules, solution, suspension, or a combination thereof.

[0043] In many embodiments, the compositions disclosed herein may further comprise pharmaceutically acceptable carriers, including but not limited to a binder, diluent, disintegrant, filler, glidant, lubricant, coloring agent, preservative, sweetener, surfactant, solvent, coating agent, or combinations thereof.

[0044] Treatment

[0045] Another aspect of this disclosure is to provide a method for treating arthritis. In many embodiments, the arthritis refers to degenerative arthritis (or osteoarthritis). The method of this disclosure comprises administering the composition of this disclosure for treating arthritis to an individual. In many specific embodiments, the composition for treating arthritis is as described herein.

[0046] In many embodiments, the system is an individual diagnosed or self-diagnosed with arthritis. In many specific embodiments, the system is a mammal, such as, but not limited to: human, dog, cat, horse, cow, monkey, rabbit, mouse, or sheep.

[0047] In many embodiments, the system is administered an effective amount of the composition. In many specific embodiments, this effective amount is 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1500, or 1750 per 60 kg body weight. Or 2000 mg, or any range defined by the two endpoints above, such as: 200 to 2000 mg, 200 to 1750 mg, 200 to 1500 mg, 200 to 1200 mg, 200 to 1000 mg, 200 to 750 mg, 200 to 500 mg, 200 to 300 mg, 300 to 2000 mg, 300 to 1750 mg, 300 to 1500 mg, 300 to 1200 mg, 300 to 1000 mg, 300 to 750 mg, 300 to 500 mg, 500 to 2000 mg, 500 to 1750 mg, 500 to 1500 mg, 500 to 1200 mg, 500 to 1000 mg, 500 to 750 mg, 800 to 2000 mg, 800 to 1750 mg, 800 to 1500 mg, 800 to 1200 mg, 800 to 1000 mg, 1000 to 2000 mg, 1000 to 1750 mg, 1000 to 1500 mg, 1000 to 1200 mg, 1500 to 2000 mg, 1500 to 1750 mg, 1500 to 1500 mg, or 1500 to 1200 mg. In many implementations, this effective dose refers to the individual's daily dosage.

[0048] In many implementations, the administration is oral. In many implementations, the administration is performed 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, or more, or any range defined by the two endpoints above, such as: 1 to 10 times, 1 to 8 times, 1 to 6 times, 1 to 4 times, 3 to 10 times, 3 to 8 times, 3 to 6 times, or 3 to 4 times. In many implementations, when the application is performed at least twice, the interval between the at least two applications is approximately 1 hour, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 2 days, 4 days, 1 week, 2 weeks, 1 month, 3 months, or 6 months, or any range defined by the two endpoints above, such as: 1 to 4 hours, 1 to 8 hours, 1 to 24 hours, 24 hours to 2 days, 2 to 4 days, 1 week to 1 month, 1 to 3 months, 1 to 6 months, or 3 to 6 months. In many implementations, when the application is performed at least three times, the interval between each two adjacent applications may be the same or different; for example, the first and second applications may be 4 hours apart, while the second and third applications may be 8 hours apart.

[0049] definition

[0050] The terms "comprising," "including," or "having" as used herein describe the existence of the referred feature, value, step, operation, member, element, and / or combination thereof, but do not exclude the possibility of the existence of other features, values, steps, operations, members, elements, and / or combinations thereof. In this document, only "consisting of..." can be interpreted as a closed definition, or only "substantially composed of..." can be interpreted as a semi-closed definition.

[0051] An "effective amount" of a composition as described herein refers to an amount that achieves the stated clinical outcome or therapeutic effect within a specific desired timeframe. An effective amount can be achieved through multiple administrations. If the individual to whom the composition is administered has been confirmed to have the stated disease or symptoms, the effective amount may be considered a "therapeutic effective amount." For an individual who is at risk of having or developing the disease or symptoms (e.g., recurrence), the effective amount administered to that individual may be considered a "preventive effective amount."

[0052] As used herein, “administer” or “drug administration” means to give the composition to an individual, either by self-administration or by taking the composition. The use of “administer” or “drug administration” herein does not limit the route, quantity, frequency, or manner in which the individual may take the composition.

[0053] Example 1: The effect of the composition disclosed herein on the treatment of arthritis

[0054] This experiment used a rat model to test the efficacy of the exemplary composition disclosed herein in treating arthritis. The rats used in this experiment (Sprague-Dawley) were purchased from BioLASCO Taiwan Co., Ltd. and bred according to the company manual. To establish an animal model of osteoarthritis, the cruciate ligament and medial meniscus of the rat's right knee were first removed, causing instability in the right knee joint and thus inducing osteoarthritis.

[0055] Next, an exemplary composition based on the present disclosure was prepared. This composition contains approximately 160 mg of an astaxanthin composition (containing 2.5% astaxanthin), 95 mg of an algal calcium composition (containing approximately 32% by weight calcium), 40 mg of non-denatured type II collagen, 80 mg of hyaluronic acid, 25 mg of calcium fructose borate, 250 mg of Terminalia chebula extract, and 350 mg of palm fruit extract per 1000 doses. The effective human dose of this exemplary composition is 1000 mg / 60 kg-Body Weight. Based on this dose, the dose for this experimental rat was approximately 105.4 mg / kg BW. The exemplary composition was administered orally once weekly to 18 rats in the experimental group, while 18 rats in the control group were given an equal volume of reverse osmosis water.

[0056] Observation. Following oral administration of the demonstrative composition or water, the rats were fed according to the company manual. Weight, water intake, and food consumption were recorded regularly to track their physiological status. The width of the rats' knee joints (including the initial width before surgery, with the right knee also recorded) was recorded weekly, and the ratio of the right knee (the surgically operated knee) to the left knee was calculated. Subsequently, at the first, second, and third months post-surgery, 3, 3, and 12 rats from each group were sacrificed, respectively, and their knee joints were observed using a histological staining method (Hematoxylin & Eosin; H&E). First, the rats' knee joints were completely removed and immobilized in 10% neutral formalin solution for 24 hours. Then, the immobilized knee joints were removed and decalcified (using Leica® rapid decalcification solution). Then, the decalcified knee joint was trimmed and prepared into paraffin tissue sections (4 micrometers). After staining with H&E, the loss width of cartilage matrix, cartilage degeneration score, total tibial cartilage degeneration width, significant tibial cartilage degeneration width, and zonal depth ratio of lesions were observed.

[0057] The width of cartilage matrix loss. Cartilage matrix loss often begins with the destruction of superficial cartilage into fibrous tissue and the loss of matrix, gradually worsening to deeper and more widespread matrix loss, eventually leading to the loss of the entire cartilage matrix. This assessment covers the extent of cartilage thickness loss, divided into superficial width (0% depth zone, spanning both sides of intact cartilage, the extent of any matrix loss), intermediate width (50% depth zone, where cartilage matrix loss has reached the intermediate layer), and tidal line width (100% depth zone, where matrix loss has severely reached the tidal line). The sum of these three widths is the extent of cartilage matrix loss, measured in micrometers.

[0058] Cartilage degeneration scoring. The primary assessment criterion is chondrocyte damage and death. The knee joint is divided into three zones along the medial tibial weight-bearing plateau: the outer zone (starting from the medial edge of the joint), the middle zone, and the medial zone (the center of the knee joint adjacent to the cruciate ligament). The severity of damage is assessed on a scale of 0-5. Each zone is scored 5 points, with 0 points for no damage and 5 points for damage exceeding 75%, the most severe. The maximum score for all three zones is 15 points.

[0059] Total width of tibial cartilage degeneration. Assess the width of any degenerative features on the tibial cartilage surface, measured in micrometers.

[0060] The width of significant tibial cartilage degeneration. Assess the extent of significant tibial cartilage surface degeneration (measured as the total thickness from the cartilage surface to the tide mark, where more than 50% of chondrocytes are damaged or dead), measured in micrometers.

[0061] The depth ratio of the lesion area. The total depth ratio of cartilage degeneration is assessed. The "Cartilage Degeneration Score" is divided into 3 areas. The score is calculated by dividing the lesion depth in each area by the total cartilage thickness (from the cartilage surface to the wave mark) in each area. No cartilage wear is 0 points, and complete wear is 1 point, with a maximum score of 3 points.

[0062] Statistical analysis: All values ​​are expressed as mean ± SEM in the graphs and as mean ± SD in the tables. One-way analysis of variance (ANOVA) was performed using Graphpad Prism 6 statistical analysis software, and the t-test (Student's t-test) was used to analyze whether there were differences between different treatments. p < 0.05 was considered statistically significant.

[0063] Experimental Results. First, according to the records, the body weight of the experimental group rats was consistently heavier than that of the control group rats (Figure 1), but there were no significant changes in either during the experimental period. Furthermore, the water intake (Figure 2) and food intake (Figure 3) of the rats remained relatively stable during the experimental period. These records indicate that the housing environment was excellent and that the demonstrative composition did not significantly affect the normal physiology of the rats. Measurements of knee joint width showed that, during the experimental period, the knee joint width ratio of the experimental group rats was lower than that of the control group rats. The difference in knee joint width ratio was statistically significant, especially at weeks 3 and 4 (Figure 4).

[0064] The results and scores of tissue section staining are shown in Tables 1, 2, 3, and 4; please also see the photographs of stained tissue sections shown in Figures 5A, 5B, 5C, 5D, 5E, 5F, and 5G. Regarding the tibial endarterial joint, the OA score for arthritis lesions in the control group was 13.4 ± 8.64, and the OA score for arthritis lesions in the experimental group was 8.0 ± 7.58. One month post-surgery, the OA score for arthritis lesions in the control group was 5.3 ± 1.15, and the OA score for arthritis lesions in the experimental group was 5.0 ± 1.00. Two months post-surgery, the OA score for arthritis lesions in the control group was 12.0 ± 6.92, and the OA score for arthritis lesions in the experimental group was 13.3 ± 9.45. The results showed no significant difference between the control and experimental groups at the tibial endarterial joint.

[0065] Regarding the femoral joint, the osteoarthritis (OA) score in the control group was 13.8 ± 5.99, while the OA score in the experimental group was 7.5 ± 4.30. One month post-surgery, the OA score in the control group was 5.0 ± 6.08, while that in the experimental group was 2.0 ± 2.00. Two months post-surgery, the OA score in the control group was 6.6 ± 5.03, while that in the experimental group was 2.0 ± 2.00. These results indicate that the experimental group showed a significant improvement in the severity of lesions in the femoral joint compared to the control group.

[0066] Regarding the articular surface lesion scores at both ends of the knee joint, the OA score at both ends of the joint was 13.6 ± 7.04 in the control group and 7.7 ± 4.66 in the experimental group. One month post-surgery, the OA score at both ends of the joint was 5.1 ± 3.40 in the control group and 3.5 ± 1.50 in the experimental group. Two months post-surgery, the median lesion severity was 9.3 ± 5.85 in the control group and 7.6 ± 5.03 in the experimental group. The results show that the experimental group exhibited a significant improvement in the severity of articular surface lesions at both ends of the knee joint compared to the control group.

[0067] Table 1: Severity of histopathological changes in the knee joint of rats in the control group. C101, C102, and C201 were 1 month after surgery; C202, C301, and C302 were 2 months after surgery (OA score = grade × stage; the average number of articular surfaces at both ends is the sum of the OA scores of the tibia and femur ends). No. C101 C102 C201 C202 C301 C302 Tibial end articular surface Grade (Severity of Lesions) Stage (lesion area) 2 2 6 1 3 2 5 4 4 2 4 2 OA score 4 6 6 20 8 8 femoral end articular surface Grade (Severity of Lesions) Stage (lesion area) OA score 1 1 1 2 1 2 4 3 12 6 2 12 3 2 6 2 1 2 Average number of joint surfaces at both ends 2.5 4 9 16 7 5

[0068] Table 2: Severity of histopathological changes in the knee joint tissue of rats in the experimental group. T101, T102, and T201 were 1 month after surgery; T202, T301, and T302 were 2 months after surgery (OA score = grade × stage; the average number of articular surfaces at both ends is the sum of the OA scores of the tibia and femur ends). No. T101 T102 T201 T202 T301 T302 Tibial end articular surface Grade (Severity of Lesions) Stage (lesion area) 4 1 2 3 5 1 6 4 2 3 5 2 OA score 4 6 5 twenty four 6 10 femoral end articular surface Grade (Severity of Lesions) Stage (lesion area) OA score 0 0 0 2 2 4 2 1 2 2 1 2 0 0 0 4 1 4 Average number of joint surfaces at both ends 2 5 3.5 13 3 7

[0069] Table 3: Severity of histopathological changes in the knee joint of rats in the control group 3 months after surgery (OA score = grade × stage; the mean number of articular surfaces at both ends is the sum of the OA scores of the tibia and femur ends). No. C401 C501 C502 C601 C602 C701 C702 C801 C802 C901 Tibial end articular surface Grade (Severity of Lesions) Stage (lesion area) 2 2 3 1 5 3 6 2 3 1 4 4 6 4 6 4 3 3 6 4 OA score 4 3 15 12 3 16 twenty four twenty four 9 twenty four femoral end articular surface Grade (Severity of Lesions) Stage (lesion area) OA score 5 2 10 2 3 6 5 2 10 4 4 16 5 2 10 5 4 20 5 4 20 5 4 20 3 2 6 5 4 20 Average number of joint surfaces at both ends 7 4.5 12.5 14 6.5 18 twenty two twenty two 7.5 twenty two

[0070] Table 4: Severity of histopathological changes in the knee joint of rats in the experimental group 3 months after surgery (OA score = grade × stage; the mean number of the articular surfaces at both ends is the sum of the OA scores of the tibia and femur ends). No. T402 T501 T502 T601 T602 T701 T801 T802 T901 T902 Tibial end articular surface Grade (Severity of Lesions) Stage (lesion area) 2 1 6 1 2 1 3 1 2 2 6 4 3 1 4 3 6 1 6 3 OA score 2 6 2 3 4 twenty four 3 12 6 18 femoral end articular surface Grade (Severity of Lesions) Stage (lesion area) OA score 5 2 10 2 2 4 0 0 0 5 3 15 4 2 8 2 4 8 2 2 4 4 3 12 3 2 6 4 2 8 Average number of joint surfaces at both ends 6 5 1 9 6 16 3.5 12 6 13

[0071] The aforementioned rat experiments showed that the disclosed composition helps alleviate the severity and extent of arthritis, particularly at the femoral end of the joint. Furthermore, a significant difference in the recovery of arthritis in rats was observed after four consecutive administrations of the drug. Therefore, these experimental results confirm that the disclosed composition helps alleviate and restore arthritis symptoms.

[0072] Implementation status

[0073] Embodiment 1: A composition for treating arthritis, comprising per 1000 mg dose: 1 to 10 mg of astaxanthin; 30 to 200 mg of a seaweed calcium composition containing at least 10% by weight of calcium; 5 to 100 mg of collagen; 20 to 150 mg of hyaluronic acid; 5 to 50 mg of calcium fructose borate; 100 to 500 mg of Terminalia chebula extract; and 100 to 500 mg of palm fruit extract.

[0074] Example 2: The composition as described in Example 1, wherein the dose per 1000 mg contains 3 to 8 mg of astaxanthin.

[0075] Example 3: The composition as described in Example 1 or 2, wherein the astaxanthin comprises 20% to 100% L-astaxanthin.

[0076] Example 4: The composition as described in any one of Examples 1 to 3, wherein the dose per 1000 mg contains 50 to 100 mg of the seaweed calcium composition.

[0077] Example 5: The composition as described in any one of Examples 1 to 4, wherein the seaweed calcium composition contains 10 to 50 percent by weight of calcium.

[0078] Example 6: The composition of any one of Examples 1 to 5, wherein the seaweed calcium composition further comprises at least one micronutrient selected from the group consisting of: magnesium, phosphorus, sulfur, iron, boron, fluoride, sodium, cobalt, copper, zinc, selenium, molybdenum, iodine, manganese, and nickel.

[0079] Example 7: The composition as described in any one of Examples 1 to 6, wherein the calcium contained in the seaweed calcium composition has a honeycomb porous structure.

[0080] Example 8: The composition of any one of Examples 1 to 7, wherein the calcium contained in the seaweed calcium composition has a polymorph comprising 60% to 70% calcite, 20% to 30% aragonite, and 10% to 20% vaterite.

[0081] Example 9: The composition as described in any one of Examples 1 to 8, wherein the dose per 1000 mg contains 20 to 60 mg of collagen.

[0082] Example 10: The composition as described in any one of Examples 1 to 9, wherein the collagen is type II collagen.

[0083] Embodiment 11: The composition as described in Embodiment 10, wherein the collagen is non-denatured type II collagen.

[0084] Embodiment 12: The composition as described in any one of Embodiments 1 to 11, wherein the dose per 1000 mg contains 50 to 100 mg of hyaluronic acid.

[0085] Example 13: The composition as described in any one of Examples 1 to 12, wherein the dose per 1000 mg contains 10 to 30 mg of calcium fructose borate.

[0086] Example 14: The composition as described in any one of Examples 1 to 13, wherein the dose per 1000 mg contains 200 to 300 mg of Terminalia chebula extract.

[0087] Example 15: The composition of any one of Examples 1 to 14, wherein the Terminalia chebula extract comprises chebulic acid, chebulic tannic acid, hydrolyzable tannin, or a combination thereof.

[0088] Example 16: The composition of any one of Examples 1 to 15, wherein the Terminalia chebula extract is obtained by the following extraction method: obtaining Terminalia chebula pericarp; grinding the Terminalia chebula pericarp to obtain a powder; extracting the powder with water to obtain a water-soluble extract of Terminalia chebula pericarp; drying the water extract of Terminalia chebula pericarp to obtain an extract powder.

[0089] Example 17: The composition of any one of Examples 1 to 16, wherein the dose per 1000 mg contains 200 to 400 mg of palm fruit extract.

[0090] Example 18: The composition of any one of Examples 1 to 17, wherein the palm fruit extract comprises palmoylethanolamide.

[0091] Example 19: The composition as described in any one of Examples 1 to 18, wherein per 1000 mg dose comprises: about 4 mg of astaxanthin; about 95 mg of a seaweed calcium composition comprising 10 to 50 percent by weight of calcium; about 40 mg of undenatured type II collagen; about 80 mg of hyaluronic acid; about 25 mg of calcium fructose borate; about 250 mg of Terminalia chebula extract; and about 350 mg of palm fruit extract.

[0092] Embodiment 20: The composition as described in any one of embodiments 1 to 19, wherein the arthritis is degenerative arthritis.

[0093] Embodiment 21: The composition as described in any one of Embodiments 1 to 20 is an oral composition.

[0094] Embodiment 22: The composition of any one of Embodiments 1 to 21 further comprises a pharmaceutically acceptable carrier.

[0095] Embodiment 23: A method of treating arthritis comprising administering to an individual a composition as described in any one of embodiments 1 to 22.

[0096] Example 24: The effective amount of the composition is 200 to 2000 mg / per 60 kg-Body Weight, as described in Example 23.

[0097] Example 25: The effective amount of the composition is 500 to 2000 mg / per 60 kg-Body Weight, as described in Example 24.

[0098] Example 26: The effective amount of the composition is 1000 mg / per 60 kg-Body Weight, as described in Example 25.

[0099] Embodiment 27: The method as described in any one of Embodiments 23 to 26, wherein the administration is oral.

[0100] Embodiment 28: The method as described in any one of Embodiments 23 to 27, wherein the system is subjected to the composition at least twice.

[0101] Embodiment 29: Use of a mixture in the preparation of a composition for treating arthritis, wherein the mixture comprises: astaxanthin; a seaweed calcium composition; collagen; hyaluronic acid; calcium fructose borate; Terminalia chebula extract; and palm fruit extract; wherein the composition for treating arthritis is the composition described in any one of Embodiments 1 to 22.

[0102] none

[0103] none

Claims

1. A composition for treating arthritis, comprising per 1000 mg dose: 3 to 8 mg of astaxanthin; 50 to 100 mg of a seaweed calcium composition containing at least 10% by weight of calcium; 20 to 50 mg of non-denatured type II collagen; 50 to 100 mg of hyaluronic acid; 10 to 30 mg of calcium fructoborate; 200 to 300 mg of Terminalia chebula extract; and 200 to 300 mg of palm fruit extract.

2. The composition as claimed in claim 1, wherein the astaxanthin comprises 20% to 100% L-astaxanthin.

3. The composition as claimed in claim 1, wherein the seaweed calcium composition contains 10 to 50 percent by weight of calcium.

4. The composition as claimed in claim 1, wherein the seaweed calcium composition further comprises at least one micronutrient selected from the group consisting of: magnesium, phosphorus, sulfur, iron, boron, fluoride, sodium, cobalt, copper, zinc, selenium, molybdenum, iodine, manganese, and nickel.

5. The composition as claimed in claim 1, wherein the Terminalia chebula extract comprises chebulic acid, chebulic tannic acid, hydrolyzable tannin, or a combination thereof.

6. The composition as claimed in claim 1, wherein the Terminalia chebula extract is obtained by the following extraction method: obtaining Terminalia chebula pericarp; grinding the Terminalia chebula pericarp to obtain a powder; extracting the powder with water to obtain a water-soluble extract of Terminalia chebula pericarp; drying the water extract of Terminalia chebula pericarp to obtain an extract powder.

7. The composition as claimed in claim 1, wherein the palm fruit extract comprises palmitamide ethanol.

8. The composition according to any one of claims 1 to 7, wherein per 1000 mg dose comprises: about 4 mg of astaxanthin; about 95 mg of a seaweed calcium composition comprising 10 to 50 percent by weight of calcium; about 40 mg of undenatured type II collagen; about 80 mg of hyaluronic acid; about 25 mg of calcium fructose borate; about 250 mg of Terminalia chebula extract; and about 350 mg of palm fruit extract.

9. The composition as claimed in claim 1, wherein the arthritis is degenerative arthritis.

10. The composition as described in claim 1, which is an oral composition.

Images